EDIT
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Editas Medicine, Inc. (EDIT) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | C- (2.0) | D- (0.7) | C+ (2.8) | A+ (5.0) | C+ (2.7) |
| 2026-11-04 | B- (3.0) | C+ (2.7) | D+ (1.7) | C+ (2.7) | A+ (5.0) | B- (3.0) |
| 2026-10-28 | B- (3.0) | C+ (2.7) | D+ (1.7) | C (2.3) | A+ (5.0) | B- (2.9) |
| 2026-10-21 | B- (3.0) | C+ (2.7) | D+ (1.7) | C (2.3) | A+ (5.0) | B- (2.9) |
| 2026-10-14 | B- (3.0) | C+ (2.7) | D+ (1.7) | C- (2.0) | A+ (5.0) | B- (2.9) |